J. Safra Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.5K Sell
428
-38
-8% -$1.63K ﹤0.01% 322
2026
Q1
$17.1K Hold
466
– – ﹤0.01% 322
2025
Q4
$23.7K Buy
+466
New +$23.8K ﹤0.01% 312
2024
Q3
– Sell
-968
Closed -$138K – 316
2024
Q2
$138K Buy
968
+634
+190% +$84K 0.01% 78
2024
Q1
$42.9K Buy
334
+293
+715% +$34.9K ﹤0.01% 95
2023
Q4
$4.24K Buy
+41
New +$4.05K ﹤0.01% 111
2016
Q3
– Sell
-4,730
Closed -$127K – 211
2016
Q2
$127K Buy
+4,730
New +$130K 0.21% 45

Other funds holding NVO

J. Safra Asset Management's NVO Position: Q2 2026 in Review

J. Safra Asset Management reduced its Novo Nordisk (NVO) stake by 8.2% in Q2 2026, selling an estimated $1.63K and leaving 428 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #322.

J. Safra Asset Management first reported a position in NVO in Q2 2016 and has held it in 7 quarters since. The position peaked at $138K in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • J. Safra Asset Management held 428 shares of Novo Nordisk worth $20.5K as of Q2 2026.
  • J. Safra Asset Management sold 38 Novo Nordisk shares in Q2 2026, an estimated $1.63K.
  • Novo Nordisk made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #322 holding.
  • J. Safra Asset Management first reported a position in Novo Nordisk in Q2 2016 and has held it in 7 quarters since.
  • J. Safra Asset Management's Novo Nordisk position peaked at $138K in Q2 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.